Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Vaccinations in London Between 8 December 2020 and 15 September 2021 5,838,305 1st doses and 5,232,885 2nd doses have been administered to London residents. Differences in vaccine roll out between London and the Rest of England London Rest of England Priority Group Vaccinations given Percentage vaccinated Vaccinations given Percentage vaccinated Group 1 Older Adult Care Home Residents 21,883 95% 275,964 96% Older Adult Care Home Staff 29,405 85% 381,637 88% Group 2 80+ years 251,021 83% 2,368,284 93% Health Care Worker 174,944 99% 1,139,243 100%* Group 3 75 - 79 years 177,665 90% 1,796,408 99% Group 4 70 - 74 years 252,609 90% 2,454,381 97% Clinically Extremely Vulnerable 278,967 88% 1,850,485 95% Group 5 65 - 69 years 285,768 90% 2,381,250 97% Group 6 At Risk or Carer (Under 65) 983,379 78% 6,093,082 88% Younger Adult Care Home Residents 3,822 92% 30,321 93% Group 7 60 - 64 years 373,327 92% 2,748,412 98% Group 8 55 - 59 years 465,276 91% 3,152,412 97% Group 9 50 - 54 years 510,132 90% 3,141,219 95% Data as at 15 September 2021 for age based groups and as at 12 September 2021 for non-age based groups * The number who have received their first dose exceeds the latest official estimate of the population for this group There is considerable uncertainty in the population denominators used to calculate the percentage vaccinated. Comparing implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following datasets can be used to estimate vaccine uptake by age group for London: ONS 2020 mid-year estimates (MYE). This is the population estimate used for age groups throughout the rest of the analysis. Number of people ages 18 and over on the National Immunisation Management Service (NIMS) ONS Public Health Data Asset (PHDA) dataset. This is a linked dataset combining the 2011 Census, the General Practice Extraction Service (GPES) data for pandemic planning and research and the Hospital Episode Statistics (HES). This data covers a subset of the population. Vaccine roll out in London by Ethnic Group Understanding how vaccine uptake varies across different ethnic groups in London is complicated by two issues: Ethnicity information for recipients is unavailable for a very large number of the vaccinations that have been delivered. As a result, estimates of vaccine uptake by ethnic group are highly sensitive to the assumptions about and treatment of the Unknown group in calculations of rates. For vaccinations given to people aged 50 and over in London nearly 10% do not have ethnicity information available, The accuracy of available population denominators by ethnic group is limited. Because ethnicity information is not captured in official estimates of births, deaths, and migration, the available population denominators typically rely on projecting forward patterns captured in the 2011 Census. Subsequent changes to these patterns, particularly with respect to international migration, leads to increasing uncertainty in the accuracy of denominators sources as we move further away from 2011. Comparing estimated population sizes and implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following population estimates are available by Ethnic group for London:

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

Vaccination rates and odds ratios by socio-demographic group among people living in England.

Dataset description

Daily official UK Covid data. The data is available per country (England, Scotland, Wales and Northern Ireland) and for different regions in England. The different regions are split into two different files as part of the data is directly gathered by the NHS (National Health Service). The files that contain the word 'nhsregion' in their name, include data related to hospitals only, such as number of admissions or number of people in respirators. The files containing the word 'region' in their name, include the rest of the data, such as number of cases, number of vaccinated people or number of tests performed per day. The next paragraphs describe the columns for the different file types.

Region files

Files related to regions (word 'region' included in the file name) have the following columns: - "date": date in YYYY-MM-DD format - "area type": type of area covered in the file (region or nation) - "area name": name of area covered in the file (region or nation name) - "daily cases": new cases on a given date - "cum cases": cumulative cases - "new deaths 28days": new deaths within 28 days of a positive test - "cum deaths 28days": cumulative deaths within 28 days of a positive test - "new deaths_60days": new deaths within 60 days of a positive test - "cum deaths 60days": cumulative deaths within 60 days of a positive test - "new_first_episode": new first episodes by date - "cum_first_episode": cumulative first episodes by date - "new_reinfections": new reinfections by specimen data - "cum_reinfections": cumualtive reinfections by specimen data - "new_virus_test": new virus tests by date - "cum_virus_test": cumulative virus tests by date - "new_pcr_test": new PCR tests by date - "cum_pcr_test": cumulative PCR tests by date - "new_lfd_test": new LFD tests by date - "cum_lfd_test": cumulative LFD tests by date - "test_roll_pos_pct": percentage of unique case positivity by date rolling sum - "test_roll_people": unique people tested by date rolling sum - "new first dose": new people vaccinated with a first dose - "cum first dose": cumulative people vaccinated with a first dose - "new second dose": new people vaccinated with a first dose - "cum second dose": cumulative people vaccinated with a first dose - "new third dose": new people vaccinated with a booster or third dose - "cum third dose": cumulative people vaccinated with a booster or third dose

Country files

Files related to countries (England, Northern Ireland, Scotland and Wales) have the above columns and also: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

NHS Region files

Files related to nhsregion (word 'nhsregion' included in the file name) have the following columns: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

It's worth noting that the dataset hasn't been cleaned and it needs cleaning. Also, different files have different null columns. This isn't an error in the dataset but the way different countries and regions report the data.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

11th January 2020 Change to vaccination data made available by UK gov - now just cumulative number of vaccines delivered are available for both first and second doses. For the devolved nations the cumulative totals are available for the dates from when given, however for the UK as a whole the total doses given is just on the last date of the index, regardless of when those vaccines were given.

4th January 2020 VACCINATION DATA ADDED - New and Cumulative First Dose Vaccination Data added to UK_National_Total_COVID_Dataset.csv and UK_Devolved_Nations_COVID_Dataset.csv

2nd December 2020:

NEW population, land area and population density data added in file NEW_Official_Population_Data_ONS_mid-2019.csv. This data is scraped from the Office for National Statistics and covers the UK, devolved UK nations, regions and local authorities (boroughs).

20th November 2020:

With European governments struggling with a 'second-wave' of rising cases, hospitalisations and deaths resulting from the SARS-CoV-2 virus (COVID-19), I wanted to make a comparative analysis between the data coming out of major European nations since the start of the pandemic.

I started by creating a Sweden COVID-19 dataset and now I'm looking at my own country, the United Kingdom.

The data comes from https://coronavirus.data.gov.uk/ and I used the Developer's Guide to scrape the data, so it was a fairly simple process. The notebook that scapes the data is public and can be found here. Further information about data collection methodologies and definitions can be found here.

The data includes the overall numbers for the UK as a whole, the numbers for each of the devolved UK nations (Eng, Sco, Wal & NI), English Regions and Upper Tier Local Authorities (UTLA) for all of the UK (what we call Boroughs). I have also included a small table with the populations of the 4 devolved UK nations, used to calculate the death rates per 100,000 population.

As I've said for before - I am not an Epidemiologist, Sociologist or even a Data Scientist. I am actually a Mechanical Engineer! The objective here is to improve my data science skills and maybe provide some useful data to the wider community.

Any questions, comments or suggestions are most welcome! I am open to requests and collaborations! Stay Safe!

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.

This dataset has been updated to reflect new age bandings and population figures provided in July 2022.

This dataset now includes details of the Autumn Booster programme.

Note on analysis:

This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:

- Aged 5 - 15 - Dose 1

- Aged 16 - 24 - Dose 1 & Dose 2

- Aged 35 - 50 - Dose 1, Dose 2 & Booster

- Aged 50+ - Dose1, Dose2, Booster & Autumn Booster

Data is updated weekly.

Antibody data, by UK country and age, from the Coronavirus (COVID-19) Infection Survey.

Context

COVID-19 is a Pandemic which was spread worldwide in the early months of 2020, Which has had a major impact on the United Kingdom. As the UK has recently carried out wide spread vaccination and ended Lockdown I am providing the recent COVID-19 figures.

Content

Several Datasets are provided, focusing on Deaths, Cases, Hospitalisation and Vaccination. Files often protray the same information but from a different reference point. For example for Deaths there is one displaying figures from people who died using there positive date as a reference point, whereas the other is using the date of death.

Acknowledgements

These datasets was scrapped off the UK Gov website in regards to COVID-19. For those looking to build a more complex project using a constant data flow, they do provide an API which may assist.

Inspiration

Possible area to explore are: What was the Impact of Vaccines on the COVID-19 Pandemic? What was the Impact of a Lockdown on the COVID-19 Pandemic? Which Nation managed the spread of COVID-19 the best?

Licence

Open Government Licence V3.0

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Context

• Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus SARS-CoV2.
• Person to person transmission occurs via several different modes, mainly when people are in close proximity to one another through respiratory droplets.
• Mitigations by various countries have been put into place to limit the spread of this virus.

Content

• ConfirmedCasesByDateReported.csv
• ConfirmedCasesBySpecimenDate.csv
• Deaths.csv
• PatientNewAdmissions.csv
• PatientsInHospital.csv
• PatientsMVBeds.csv
• PCRTesting.csv
• Vaccinations.csv
• VaccinationsDaily.csv

Acknowledgements and Collection Methodology

Data downloaded from https://coronavirus.data.gov.uk

Version

• Version 11 - 25 - Various Files Updated.
• Version 10 - Added VaccinationsDaily File, data upto and including the 20th Jan 2021.
• Version 9 - Updated Deaths file, data upto and including the 20th Jan 2021.
• Version 8 - Updated ConfirmedCasesByDateReported and ConfirmedCasesBySpecimenDate files, data upto and including the 17th to 19th Jan 2021 respectively.
• Version 7 - Updated PatientNewAdmissions, PatientsInHospital and PatientsMVBeds files, data upto and including the 12th to 15th Jan 2020 depending on file.
• Version 6 - Updated PCR Testing file, data upto and including the 14th Jan 2021.
• Version 4 - Updated Vaccinations file, data upto and including the 3rd Jan 2021.
• Version 3 - Updated to include data unto and including the 28th December 2020. Additionally added data on the progress of Vaccinations.
• Version 2 - Updated to include data unto and including the 3rd November 2020.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

University students, who face an elevated risk of influenza due to close living quarters and frequent social interactions, often exhibit low vaccine uptake rates. This issue is particularly pronounced among Chinese students, who encounter unique barriers related to awareness and access, emphasizing the need for heightened attention to this problem within this demographic. This cross-sectional study conducted in May-June 2022 involved 1,006 participants (404 in the UK, 602 in Mainland China) and aimed to explore and compare the factors influencing influenza vaccine acceptance and intentions between Chinese university students residing in the UK (C-UK) and Mainland China (C-M). The study employed a self-administered questionnaire based on the Theoretical Domains Framework and Capability Opportunity Motivation-Behavior model. Results revealed that approximately 46.8% of C-UK students received the influenza vaccine in the past year, compared to 32.9% of C-M students. More than half in both groups (C-UK: 54.5%, C-M: 58.1%) had no plans for vaccination in the upcoming year. Knowledge, belief about consequences, and reinforcement significantly influenced previous vaccine acceptance and intention in both student groups. Barriers to vaccination behavior included insufficient knowledge about the influenza vaccine and its accessibility and the distance to the vaccine center. Enablers included the vaccination behavior of individuals within their social circles, motivation to protect others, and concerns regarding difficulties in accessing medical resources during the COVID-19 pandemic. The findings of this study offer valuable insights for evidence-based intervention design, providing evidence for healthcare professionals, policymakers, and educators working to enhance vaccination rates within this specific demographic.

IntroductionThe key to understanding the COVID-19 correlates of protection is assessing vaccine-induced immunity in different demographic groups. Young people are at a lower risk of COVID-19 mortality, females are at a lower risk than males, and females often generate stronger immune responses to vaccination.MethodsWe studied immune responses to two doses of BNT162b2 Pfizer COVID-19 vaccine in an adolescent cohort (n = 34, ages 12–16), an age group previously shown to elicit significantly greater immune responses to the same vaccine than young adults. Adolescents were studied with the aim of comparing their response to BNT162b2 to that of adults; and to assess the impacts of other factors such as sex, ongoing SARS–CoV–2 infection in schools, and prior exposure to endemic coronaviruses that circulate at high levels in young people. At the same time, we were able to evaluate immune responses to the co-administered live attenuated influenza vaccine. Blood samples from 34 adolescents taken before and after vaccination with COVID-19 and influenza vaccines were assayed for SARS–CoV–2-specific IgG and neutralising antibodies and cellular immunity specific for SARS–CoV–2 and endemic betacoronaviruses. The IgG targeting influenza lineages contained in the influenza vaccine were also assessed.ResultsRobust neutralising responses were identified in previously infected adolescents after one dose, and two doses were required in infection-naïve adolescents. As previously demonstrated, total IgG responses to SARS–CoV-2 Spike were significantly higher among vaccinated adolescents than among adults (aged 32–52) who received the BNT162b2 vaccine (comparing infection-naïve, 49,696 vs. 33,339; p = 0.03; comparing SARS-CoV–2 previously infected, 743,691 vs. 269,985; p <0.0001) by the MSD v-plex assay. There was no evidence of a stronger vaccine-induced immunity in females compared than in males.DiscussionThese findings may result from the introduction of novel mRNA vaccination platforms, generating patterns of immunity divergent from established trends and providing new insights into what might be protective following COVID-19 vaccination.

Includes: Patient demographics, Source Organisation, vaccination details and vaccine batch events. Its scope covers: Anyone vaccinated within England Anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include: hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

Flu vaccine uptake (%) in school aged children from Reception to Year 6 (age 4 to 11 year olds) between 1st September to the end of January.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in school aged children in Reception to Year 6 (age 4 to 11 years old).Definition of numeratorThe total number of children in the respective eligible age cohort that have received at least one dose of influenza vaccine from 1 September in school, pharmacy, and general practice.Definition of denominatorThe total number of children eligible for influenza vaccination in the LA geography and children educated out of school in the LA geography, defined by child age on 31 AugustCaveatsData for ICBs are estimated from local authority data. In most cases, ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on the population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and WiltshireBedfordshire, Luton and Milton KeynesBuckinghamshire, Oxfordshire and Berkshire WestCambridgeshire and PeterboroughFrimleyHampshire and Isle of WightHertfordshire and West EssexHumber and North YorkshireLancashire and South CumbriaNorfolk and WaveneyNorth East and North CumbriaSuffolk and North East EssexSurrey HeartlandsSussexWest YorkshireRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus may fall outside the listed read codes. Therefore, it is important to note that for the reasons mentioned, this data should not be used for GP payment purposes.This collection is regularly submitted for approval from the Data Coordination Board (DCB).